Clinical Research Directory
Browse clinical research sites, groups, and studies.
GN001 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia
Sponsor: Department of Hematology,Rheumatology and Immunology,Pu'er People's Hospital
Summary
This study will evaluate GN001 in adults aged 18 to 75 years with CD19-positive relapsed or refractory B-cell non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia. GN001 is an investigational lentiviral vector-based treatment designed to generate CD19-targeted chimeric antigen receptor (CAR) T cells within the body. The main purpose is to assess safety and tolerability at different doses. The study will also assess antitumor activity, the expansion and persistence of CAR T cells, and biological responses to treatment. Participants will receive GN001 by intravenous infusion. The study includes dose escalation and may include dose expansion after safety review. Long-term safety follow-up is planned.
Official title: An Exploratory Clinical Study of GN001 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
42
Start Date
2026-08-04
Completion Date
2029-08
Last Updated
2026-11-02
Healthy Volunteers
No
Conditions
Interventions
GN001
GN001 administered as a single intravenous infusion.
Locations (2)
The 920th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army
Kunming, Yunnan, China
Pu'er People's Hospital
Pu'er, Yunnan, China